Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 4/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.41 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.41 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.38 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
| ▸ | KMO | O15229 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12522824 | 0.90 | HDAC1 (0.58) | HDAC1HDAC8HDAC6ALDH1A1PDE4B | |
| SCHEMBL12452885 | 0.89 | ALDH1A1 (0.38) | HDAC1HDAC8HDAC6ALDH1A1PDE4B | |
| SCHEMBL2436714 | 0.86 | ALDH1A1 (0.36) | HDAC1HDAC8HDAC6ALDH1A1PDE4B | |
| SCHEMBL2870864 | 0.79 | HDAC1 (0.74) | HDAC1HDAC8HDAC6ALDH1A1PDE4B | |
| SCHEMBL12522843 | 0.77 | ALDH1A1 (0.45) | HDAC1HDAC8HDAC6ALDH1A1PDE4B | |
| SCHEMBL16898659 | 0.76 | ALDH1A1 (0.45) | HDAC1HDAC8HDAC6ALDH1A1PDE4B | |
| SCHEMBL12522679 | 0.74 | HDAC1 (0.53) | HDAC1HDAC8HDAC6ALDH1A1PDE4B | |
| Valine SCHEMBL313633 | 0.74 | SLC7A5 (0.35) | ALDH1A1PTPN1 | |
| SCHEMBL287420 | 0.73 | ALDH1A1 (0.74) | HDAC1HDAC8HDAC6ALDH1A1PDE4B | |
| SCHEMBL31558487 | 0.73 | PDE4B (0.63) | HDAC1HDAC8HDAC6ALDH1A1PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8796300-B2 | Therapeutic compounds | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2014-08-05 | — | — | US | disclosed |
| US-20120238595-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2012-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238595-A1 | THERAPEUTIC COMPOUNDS | CCNY, MKI67, MCL1 | HDAC1 201/4885HDAC8 685/4885HDAC6 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.